Results 211 to 220 of about 40,867 (262)

Intraoperative MRI for giant cell tumor of bone after denosumab and other selected tumors: A pilot study. [PDF]

Acta Radiol Open
Furuta T, Sakuda T, Adachi N.
europepmc   +1 more source

Case report of severe hypocalcemia with atypical symptoms after zoledronic acid in palliative care: a deprescribing pitfall. [PDF]

BMC Palliat Care
Arnold T, Berner-Sharma J, Rudolph D, Bausewein C, Rémi C.   +4 more
europepmc   +1 more source

An Adrenal Crisis After Denosumab Use in a Patient With Addison's Disease: A Case Report. [PDF]

Cureus
Caglar H, Hira S, Caglar SO.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Denosumab Discontinuation

Current Osteoporosis Reports, 2022
To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation.Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss.
Anne Sophie Sølling, Elena Tsourdi, Torben Harsløf, Bente L Langdahl   +3 more
openaire   +3 more sources

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

New England Journal of Medicine, 2009
Michael McClung, Richard Eastell, Ian Reid   +2 more
exaly   +2 more sources

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Journal of Bone and Mineral Research, 2018
Serge Ferrari, Richard Eastell, Jens-Erik Beck Jensen   +2 more
exaly   +2 more sources

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Lancet, The, 2011
Matthew D Smith, Janet E Brown, Lawrence I Karsh   +2 more
exaly   +2 more sources